Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes

Journal of Diabetes Investigation

Volumn 4, Issue 4, 2013, Pages 399-404

  Ushigome, Emi ^a   Fukui, Michiaki ^a   Hamaguchi, Masahide ^b   Tanaka, Toru ^c   Atsuta, Haruhiko ^d   Ohnishi, Masayoshi ^e   Oda, Yohei ^f   Yamazaki, Masahiro ^a   Hasegawa, Goji ^a   Nakamura, Naoto ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^c KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^d Social Insurance Kyoto Hospital   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f WEST JAPAN RAILWAY COMPANY   (Japan)

Author keywords

Blood pressure variability; Home blood pressure monitoring; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 84880160883     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12052     Document Type: Article

References (30)

1. Lawes CM, Vander Hoorn S, Rodgers A, for International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-1518.
2. Asia Pacific Cohort Studies Collaboration, Kengne AP, Patel A, Barzi F, et al. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 2007; 25: 1205-1213.
3. Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001; 19: 1981-1989.
4. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA Study. Hypertension 2002; 39: 710-714.
5. Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama Study. Hypertension 2000; 36: 901-906.
6. Webb AJ, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-915.
7. Zhang Y, Agnoletti D, Safar ME, et al. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011; 58: 155-160.
8. Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-1583.
9. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578.
10. Ushigome E, Fukui M, Hamaguchi M, et al. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res 2011; 12: 1271-1275.
11. Ushigome E, Fukui M, Sakabe K, et al. Uncontrolled home blood pressure in the morning is associated with nephropathy in Japanese type 2 diabetes. Heart Vessels 2011; 11: 609-615.
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002; 25: S5-S20.
13. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
14. Coleman A, Freeman P, Steel S, et al. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit 2006; 11: 27-32.
15. Imai Y, Otsuka K, Kawano Y, et al. Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771-782.
16. Verdecchia P, Angeli F, Gattobigio R, et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens 2007; 20: 154-161.
17. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 5: 469-480.
18. Frattola A, Parati G, Castiglioni P, et al. Lacicipine and blood pressure variability in diabetic hypertensive patients. Hypertension 2000; 36: 622-628.
19. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
20. Parati G, Bilo G. Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring. Hypertension 2012; 6: 1091-1093.
21. Frontoni S, Bracaglia D, Gigli F. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutr Metab Cardiovasc Dis. 2005; 6: 441-449.
22. Weck M. Treatment of hypertension in patients with diabetes mellitus: relevance of sympathovagal balance and renal function. Clin Res Cardiol 2007; 10: 707-718.
23. Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol 2006; 21: 486-491.
24. Xu LP, Shen FM, Shu H, et al. Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. Fundam Clin Pharmacol 2004; 18: 33-38.
25. Liu JG, Xu LP, Chu ZX, et al. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003; 21: 1961-1967.
26. Johansson JK, Niiranen TJ, Puukka PJ, et al. Factors affecting the variability of home-measured blood pressure and heart rate: the Finn-home study. J Hypertens 2010; 9: 1836-1845.
27. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32: 950-955.
28. Schillaci G, Parati G, Pirro M, et al. Ambulatory arterial stiffness index is not a specific marker of reduced arterial compliance. Hypertension 2007; 5: 986-991.
29. van der Hoeven NV, van den Born BJ, Cammenga M, et al. Poor adherence to home blood pressure measurement schedule. J Hypertens 2009; 27: 275-279.
30. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.